Abbvie Inc reports results for the quarter ended June 30 - Earnings Summary
Abbvie Inc reports results for the quarter ended June 30 - Earnings Summary
Abbvie Inc ABBV.N reported quarterly adjusted earnings of $3.65 per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $2.97. The mean expectation of twenty two analysts for the quarter was for earnings of $3.60 per share. Wall Street expected results to range from $3.57 to $3.65 per share.
Revenue rose 10.2% to $16.99 billion from a year ago; analysts expected $16.77 billion.
Abbvie Inc's reported EPS for the quarter was $2.03.
The company reported quarterly net income of $3.61 billion.
Abbvie Inc shares had risen by 2.3% this quarter and gained 12.7% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 4% in the last three months.
In the last 30 days, nineteen analysts negatively revised earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 26 "strong buy" or "buy," 6 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"
Wall Street's median 12-month price target for Abbvie Inc is $275.50, about 6.6% above its last closing price of $257.41
This summary was machine generated from LSEG data July 31 at 06:19 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Jun. 30 2026 | 3.60 | 3.65 | Beat |
Mar. 31 2026 | 2.59 | 2.65 | Beat |
Dec. 31 2025 | 2.65 | 2.71 | Beat |
Sep. 30 2025 | 1.77 | 1.86 | Beat |
Recent news on AbbVie
See all newsAbbVie's skin disease drug reduces lesions in trial, company eyes weight-loss combination
Factbox: Pharma sector doubles down on AI to slash costs, timelines
Brief: Abbvie Reaches Agreement With The Pan-Canadian Pharmaceutical Alliance (Pcpa) For Elahere® In Platinum-Resistant Ovarian Cancer
Eli Lilly hits record high as healthcare stocks rally
Nvidia-backed Iambic Therapeutics tumbles below IPO price